Journal of Nanomedicine & Biotherapeutic Discovery
ISSN: 2155-983X
OPEN ACCESS Freely available online
Short Communication

Applications of Nanoparticles in Biopharmaceuticals

Patrice Mangin*

Department of Pharmaceutics, University of Gondar, Maraki, Gondar, Ethiopia

ABOUT THE STUDY

Nano biopharmaceuticals are a rapidly growing field at the intersection of nanotechnology and biopharmaceuticals. They are a class of drugs that utilize nanoparticles to enhance the delivery, targeting, and efficacy of biopharmaceuticals, such as proteins, peptides, and nucleic acids. Nano biopharmaceuticals have shown great promise in improving the treatment of various diseases, including cancer, infectious diseases, and genetic disorders [1]. One of the main advantages of Nano biopharmaceuticals is their ability to overcome biological barriers and improve drug delivery. Many biopharmaceuticals, such as proteins and peptides, have poor stability, low solubility, and limited bioavailability, which can limit their therapeutic potential. However, nanoparticles can protect these biopharmaceuticals from degradation and clearance, prolong their circulation time, and enhance their accumulation at the target site. This enhanced delivery can result in higher efficacy, lower toxicity, and reduced dosing frequency, leading to improved patient outcomes [2].

Another advantage of Nano biopharmaceuticals is their ability to target specific cells or tissues. Nanoparticles can be functionalized with ligands, antibodies, or peptides that bind to specific receptors or markers on the surface of target cells. This targeted delivery can improve the therapeutic index of biopharmaceuticals, by reducing off-target effects and improving the selectivity of the treatment. For example, Nano biopharmaceuticals can be targeted to cancer cells, allowing for more efficient and specific tumor cell killing while sparing healthy cells [3]. In addition, Nano biopharmaceuticals can be designed to overcome multidrug resistance mechanisms, which can limit the efficacy of many chemotherapeutic agents. Nanoparticles can encapsulate chemotherapeutic agents and deliver them directly to the cancer cells, bypassing the efflux pumps that often cause multidrug resistance. This approach has been shown to improve the therapeutic outcomes of several chemotherapeutic agents, such as doxorubicin and paclitaxel [4].

Furthermore, Nano biopharmaceuticals have the potential to revolutionize the treatment of genetic disorders, such as gene therapy and RNA interference. Nanoparticles can efficiently deliver deliver nucleic acids, such as plasmids or siRNA, to target cells, allowing for the manipulation of gene expression and regulation. One of the main challenges is the complexity of the nanoparticles themselves. Nanoparticles can have multiple components, such as the drug payload, the targeting ligand, the stabilizing agent, and the surface coating, which can affect their pharmacokinetics, toxicity, and immunogenicity. Therefore, it is important to carefully optimize the nanoparticle design and characterization to ensure their safety and efficacy. Another challenge is the regulatory approval process for Nano biopharmaceuticals. The unique properties of nanoparticles can make it difficult to apply traditional regulatory frameworks, which may require new safety and efficacy assessment methods. Furthermore, the high cost of nanoparticle manufacturing and the lack of standardization in nanoparticle characterization can hinder their translation from the laboratory to the clinic [5].

CONCLUSION

Nano biopharmaceuticals are a promising technology with the potential to revolutionize the treatment of various diseases. Their ability to enhance drug delivery, target specific cells or tissues, and overcome multidrug resistance mechanisms can lead to improved patient outcomes and reduced healthcare costs. However, the development and application of Nano biopharmaceuticals require careful consideration of the nanoparticle design and characterization, as well as the regulatory approval process. This approach has the potential to treat many genetic disorders, such as cystic fibrosis, muscular dystrophy, and hemophilia, which are currently incurable. Despite the potential of Nano biopharmaceuticals, there are still challenges associated with their development and application.

REFERENCES

1. Patra JK, Das G, Fraceto LF, Campos EV, Rodriguez-Torres MD, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):1-33.
2. Dutta S. Immunotherapy of tumors by tailored nano-zeolitic imidazolate framework protected biopharmaceuticals. Biomater Sci. 2021;9(19):6391-6402.

Correspondence to: Patrice Mangin, Department of Pharmaceutics, University of Gondar, Maraki, Gondar, Ethiopia, E-mail: Mangin6@gmail.com

Received: 01-Mar-2023, Manuscript No. JNBD-23-23300; **Editor assigned:** 03-Mar-2023, PreQC No. JNBD-23-23300 (PQ); **Reviewed:** 23-Mar-2023, QC No. JNBD-23-23300; **Revised:** 03-Apr-2023, Manuscript No. JNBD-23-23300 (R); **Published:** 12-Apr-2023, DOI: 10.4172/2155-983X.23.13.189

Citation: Mangin P (2023) Applications of Nanoparticles in Biopharmaceuticals. J Nanomedicine Biotherapeutic Discov. 13:189.

3. Chung YH, Beiss V, Fiering SN, Steinmetz NF. COVID-19 vaccine frontrunners and their nanotechnology design. ACS Nano. 2020;14(10):12522-12537.
4. Hussain A, Yang H, Zhang M, Liu Q, Alotaibi G, Irfan M, et al. mRNA vaccines for COVID-19 and diverse diseases. J Controlled Release. 2022.
5. Fang RH, Hu CM, Luk BT, Gao W, Copp JA, Tai Y, et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014;14(4):2181-2188.